Recent OCGN News
- Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema • GlobeNewswire Inc. • 01/16/2025 12:30:38 PM
- Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa • GlobeNewswire Inc. • 01/13/2025 11:30:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2025 10:02:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2025 10:02:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2025 10:01:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2025 10:01:03 PM
- Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration • GlobeNewswire Inc. • 12/19/2024 11:38:37 AM
- Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit • GlobeNewswire Inc. • 12/11/2024 12:02:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/03/2024 02:50:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2024 09:15:25 PM
- Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference • GlobeNewswire Inc. • 11/27/2024 12:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2024 09:50:10 PM
- Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease • GlobeNewswire Inc. • 11/20/2024 12:30:00 PM
- Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration • GlobeNewswire Inc. • 11/19/2024 12:02:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2024 09:17:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2024 09:05:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 08:25:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 02:55:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2024 09:30:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2024 06:43:16 PM
- Ocugen Provides Business Update with Third Quarter 2024 Financial Results • GlobeNewswire Inc. • 11/08/2024 11:45:51 AM
- Ocugen Secures $30 Million in Debt Funding • GlobeNewswire Inc. • 11/07/2024 11:30:55 AM
- Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 • GlobeNewswire Inc. • 10/28/2024 10:30:00 AM
UC Asset Announces Plan of Secondary Public Offering via Reg A • UCASU • Jan 23, 2025 9:30 AM
Luke Plants Featured in U.S. Department of the Interior Report to Congress on Strategic Review of National Orphan Well Program • ZEFIF • Jan 21, 2025 10:51 AM
North Bay Resources Acquires 70% Interest in the Bishop Gold Mill, Inyo County, California • NBRI • Jan 21, 2025 9:26 AM
HealthLynked Unveils Release of ARi: A Revolutionary AI-Powered Healthcare Assistant • HLYK • Jan 21, 2025 8:00 AM
Good Gaming Inc. Announces ViaOne Services' Intent to Purchase Up to 10% of Its Common Shares in the Open Market • GMER • Jan 16, 2025 8:30 AM
Avant Technologies and Ainnova Begin Implementing and Testing Advanced AI Algorithms for Early Detection of Additional Diseases • AVAI • Jan 16, 2025 8:00 AM